Skip to content
ClinCalc Pro
Menu
Intranasal Antihistamine

Azelastine Nasal Spray

Brand names: Rhinolast, Dymista (combined with fluticasone)

Azelastine nasal spray is a topical second-generation antihistamine delivered directly to the nasal mucosa for the relief of seasonal and perennial allergic rhinitis.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It antagonises histamine H1 receptors and stabilises mast cells locally in the nasal lining, blunting sneezing, itch, rhinorrhoea and congestion, with a rapid onset of action.

Prescribing in practice

  • A bitter or unpleasant taste is the most common and characteristic side effect and the main reason for poor adherence; correct technique reduces it.
  • Acts locally with rapid onset and minimal systemic absorption, so systemic sedation is uncommon at recommended use.
  • Mild nasal irritation, stinging or epistaxis can occur with topical nasal use.

Monitoring

No laboratory monitoring is needed; review symptom control, inhaler-style technique and local tolerability.

Counselling the patient

  • Prime the spray before first use and direct it slightly away from the nasal septum.
  • Keep your head tilted forward and avoid sniffing hard to lessen the bitter taste running down the throat.
  • Use it regularly through the allergy season rather than only when symptomatic.

Evidence & guidelines

Intranasal antihistamines are recommended in allergic rhinitis guidance as effective options with rapid onset, often combined with an intranasal corticosteroid for more severe symptoms.

Reference: MOZILLA Trials (Carr et al. J Allergy Clin Immunol 2012); BSACI Rhinitis Guidelines 2017; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.